You're asking about **(1e,4e)-1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one**, a fascinating organic molecule that deserves a detailed explanation. Here's a breakdown:
**What it is:**
* **(1e,4e)-1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one** is a complex organic compound with the following structure:
* **Penta-1,4-dien-3-one:** This part indicates a five-carbon chain (penta) with two double bonds at positions 1 and 4, and a ketone functional group (C=O) at position 3. The dien part indicates the presence of two double bonds, and the one part indicates the presence of a ketone functional group.
* **(1e,4e):** These letters indicate the stereochemistry of the double bonds. The 'e' stands for 'trans' configuration, meaning the two substituents on each double bond are on opposite sides of the double bond.
* **Bis(2-methoxyphenyl):** This means two 2-methoxyphenyl groups are attached to the molecule, one at each end of the carbon chain. A 2-methoxyphenyl group is a phenyl ring (C6H5) with a methoxy group (CH3O) attached at position 2.
* **Overall:** The molecule is a conjugated system with extended pi-electron delocalization, leading to potential interesting electronic and optical properties.
**Importance in Research:**
While not widely known, this specific compound holds significant potential in research due to its unique structure and properties. Here's why it's interesting:
* **Potential as a photosensitizer:** The extended conjugated system and presence of the ketone group make it a candidate for photochemical reactions. Photosensitizers are crucial in applications like photodynamic therapy, a promising cancer treatment method.
* **Biological activity:** The molecule contains the methoxyphenyl groups, which are commonly found in bioactive compounds. It might exhibit interesting biological activity like antimicrobial or antioxidant effects.
* **Materials science:** The extended pi-system could be used for developing organic semiconductors, organic solar cells, or other materials with interesting optoelectronic properties.
* **Synthetic Chemistry:** The molecule's structure can serve as a model for studying organic reactions, particularly those involving conjugated systems.
**To find specific research on this compound, you can:**
* **Use online databases like SciFinder, Reaxys, or PubMed:** Search using the full name of the compound or its molecular formula.
* **Look for relevant research papers that mention related compounds or chemical reactions:** Use keywords like pentadienone, conjugated systems, photosensitizers, biological activity, or materials science.
Remember, understanding the chemical structure and properties of this compound is essential to appreciating its potential in different fields.
ID Source | ID |
---|---|
PubMed CID | 830608 |
CHEMBL ID | 477053 |
SCHEMBL ID | 2744044 |
SCHEMBL ID | 2744047 |
MeSH ID | M0573249 |
Synonym |
---|
41973-42-6 |
nsc-97906 |
nsc97906 |
AKOS000513710 |
CHEMBL477053 , |
go-y019 |
(1e,4e)-1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one , |
bdbm50285603 |
STK975496 |
39777-61-2 |
AB00092085-01 |
1,5-bis-(2-methoxyphenyl)-1,4-pentadien-3-one |
SCHEMBL2744044 |
SCHEMBL2744047 |
F9994-5418 |
rpn77612 |
tfeb activator 1 |
HY-135825 |
BS-17008 |
tfeb activator 1; abm-7612 |
mfcd00719180 |
CS-0114292 |
D82401 |
S6769 |
(1e,4e)-1,5-bis(2-methoxyphenyl)penta-1, |
Excerpt | Reference | Relevance |
---|---|---|
" Curcumin has been examined in a number of clinical studies with limited success, mainly owing to limited bioavailability and rapid metabolism." | ( Activation of anti-oxidant Nrf2 signaling by enone analogues of curcumin. Deck, LM; Hunsaker, LA; Royer, RE; Vander Jagt, DL; Vander Jagt, TA; Whalen, LJ, 2018) | 0.48 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Nuclear factor erythroid 2-related factor 2 | Homo sapiens (human) | EC50 (µMol) | 3.3000 | 0.0600 | 2.6167 | 9.9000 | AID1348956 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID416202 | Cytotoxicity against human HeLa cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. |
AID416174 | Hydrolytic stability assessed as compound degradation at 2 mg in sodium dihydrogen phosphate buffered 0.3% sodium carboxymethylcellulose solution at pH 7.4 after 45 hrs by HPLC | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. |
AID594784 | Cytotoxic activity against human HeLa cells after 24 to 48 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Dibenzylideneacetone analogues as novel Plasmodium falciparum inhibitors. |
AID594786 | Antiplasmodial activity against blood stage of chloroquine-sensitive Plasmodium falciparum 3D7 infected in human O positive erythrocytes after 48 hrs by SYBR green-I based fluorescence assay | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Dibenzylideneacetone analogues as novel Plasmodium falciparum inhibitors. |
AID1348958 | Effect on firefly luciferase activity expressed in human HepG2 cells at low concentration after 5 hrs by luminescence assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Activation of anti-oxidant Nrf2 signaling by enone analogues of curcumin. |
AID416198 | Cytotoxicity against human KB cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. |
AID458185 | Growth inhibition of human HCT116 cells after 48 hrs by MTS assay | 2010 | Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3 | Structure-activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof. |
AID594785 | Antiplasmodial activity against blood stage of chloroquine-resistant Plasmodium falciparum isolate RKL9 infected in human O positive erythrocytes after 48 hrs by SYBR green I-based fluorescence assay | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Dibenzylideneacetone analogues as novel Plasmodium falciparum inhibitors. |
AID1348957 | Activation of Nrf2 (unknown origin) expressed in human HepG2 cells at 15 uM after 5 hrs by ARE-driven luciferase reporter gene assay relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Activation of anti-oxidant Nrf2 signaling by enone analogues of curcumin. |
AID416199 | Cytotoxicity against human HL60 cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. |
AID1348956 | Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Activation of anti-oxidant Nrf2 signaling by enone analogues of curcumin. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.84) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |